[ 鐧诲綍] [ 鍏嶈垂娉ㄥ唽]
璇曞墏浠櫒缃? title=
浣嶇疆锛欬a href="/">棣栭〉> 浜у搧搴掽/a> > Quinidine-d3
绔嬪嵆鍜ㄨ
鍜ㄨ绫诲瀷锛欬/div>
*濮撳悕锛欬/div>
*鐢佃瘽锛欬/div>
*鍗曚綅锛欬/div>
Email锛欬/div>
*鐣欒█鍐呭锛欬/div>
璇疯缁嗚鏄庢偍鐨勯渶姹傘€
*楠岃瘉鐮侊細
Quinidine-d3
鏈骇鍝佷笉鍚戜釜浜洪攢鍞紝浠呯敤浣滅瀛︾爺绌讹紝涓嶇敤浜庝换浣曚汉浣撳疄楠屽強闈炵鐮旀€ц川鐨勫姩鐗╁疄楠屻€侟/div>
Quinidine-d3鍥剧墖
鍖呰: 2.5mg
瑙勬牸: 98%
甯傚満浠耳 4074鍏傸/td>
鍒嗗瓙閲廁 327.4

浜у搧浠嬬粛
An internal standard for the quantification of quinidine
璐у彿:ajcx20088
CAS:1267657-68-0
鍒嗗瓙寮廁C20H21D3N2O2
鍒嗗瓙閲忥細327.4
婧惰В搴?Chloroform: slightly soluble,Methanol: slightly, heated
绾害锛?8%
瀛樺偍锛歋tore at -20掳C
搴撳瓨锛欬span> 鐜拌揣

Background:

Quinidine-d3 is intended for use as an internal standard for the quantification of quinidine by GC- or LC-MS. Quinidine is a stereoisomer of the antimalarial agent quinine and a class Ia antiarrhythmic agent.1,2 Quinidine blocks the voltage-gated sodium (Nav) channel Nav1.5 in a use-dependent manner.1 It decreases the amplitude and duration of action potentials in isolated canine ventricular myocytes.3 Quinidine inhibits KKr, peak INa, and late INa (IC50s = 4.5, 11, and 12 渭M, respectively) and can induce torsade de pointes in isolated rabbit hearts when used at a concentration of 1 渭M.2 It induces QT prolongation in dogs.4 Quinidine also binds to M2 muscarinic acetylcholine receptors (Ki = 7.5 渭M for human recombinant receptors expressed in HM2-B10 cells).5 Formulations containing quinidine have been used in the treatment of atrial fibrillation and ventricular arrhythmias.


|1. Roden, D.M. Pharmacology and toxicology of Nav1.5-class 1 anti-arrhythmic drugs. Card. Electrophysiol. Clin. 6(4), 695-704 (2014).|2. Wu, L., Guo, D., Li, H., et al. Role of late sodium current in modulating the proarrhythmic and antiarrhythmic effects of quinidine. Heart Rhythm 5(12), 1726-1734 (2008).|3. Salata, J.J., and Wasserstrom, J.A. Effects of quinidine on action potentials and ionic currents in isolated canine ventricular myocytes. Circ. Res. 62(2), 324-337 (1988).|4. Rakhit, A., Guentert, T.W., Holford, N.H.G., et al. Pharmacokinetics and pharmacodynamics of quinidine and its metabolite, quinidine-N-oxide, in beagle dogs. Eur. J. Drug Metab. Pharmacokinet. 9(4), 315-324 (1984).|5. Kovacs, I., Yamamura, H.I., Waite, S.L., et al. Pharmacological comparison of the cloned human and rat M2 muscarinic receptor genes expressed in the murine fibroblast (B82) cell line. J. Pharmacol. Exp. Ther. 284(2), 500-507 (1998).

Baidu
map